Biotechnology company, Capricor Therapeutics Inc. (CAPR), Tuesday announced that it had been granted an in-person Type-B meeting with the U.S. Food and Drug Administration regarding the commercial launch of CAP-1002.
The company stated that it plans to accelerate the process of Biologics License Application or BLA submission with this meeting.
Earlier, CAP-1002 drug had received Regenerative Medicine Advanced Therapy or RMAT, and orphan drug designations for the treatment of patients with Duchenne muscular dystrophy or DMD, which is a genetic disorder involving muscle weakness and degeneration.
Currently, Capricor's stock is trading at $4.3877, up 10.80 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.